Saffron Social Anxiety Randomized Trial: What the Evidence Says

Quick Answer

Saffron Social Anxiety Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 narrative review, 1 research article.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• An increasing body of evidence suggests that these features may be modulated by sex-related differences. [Scenna Marta Sofia (2026); evidence level 3]
• In addition, it can also be associated with other medical conditions including epilepsy, congenital cardiac defects, gastrointestinal (GI), immunological, endocrine/metabolic and sleep disorders, as well as psychiatric comorbidities like ADHD and anxiety. [Scenna Marta Sofia (2026); evidence level 3]
• Thus, providing effective interventions for anxiety management to autistic people is essential, however there are very few existing support options available, and their current evidence-base is limited (Benevides et al. ). [Oakley Bethany (2025); evidence level 4]
• The limited availability of effective, evidence-based anxiety interventions for autistic people may be partly due to differences between autistic and non-autistic people in the mechanistic underpinnings of anxiety symptoms that represent key targets for support. [Oakley Bethany (2025); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For saffron social anxiety randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Scenna Marta Sofia (2026). Mitochondrial dysfunction and oxidative stress in autism spectrum disorder: pharmacological insights into natural antioxidants. DOI: 10.3389/fphar.2026.1783888. PMCID: PMC13124719. PMID: 42064796. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13124719/
• Oakley Bethany (2025). Feasibility Study of a Novel App‐Based Anxiety Intervention for Autistic People. DOI: 10.1002/aur.70153. PMCID: PMC12853239. PMID: 41392571. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12853239/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.